Loading clinical trials...
Loading clinical trials...
A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the FGFR 1, 2 or 3 Genes
Conditions
Interventions
Debio1347 (CH5183284)
Locations
8
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Memorial Sloan-Kettering Hospital
New York, New York, United States
The University of Texas; MD Anderson Cancer Center
Houston, Texas, United States
National Cancer Center Singapore
Singapore, Singapore
Seoul National University Hospital
Seoul, South Korea
Start Date
August 1, 2013
Primary Completion Date
June 26, 2020
Completion Date
June 26, 2020
Last Updated
September 9, 2020
NCT07403370
NCT06815575
NCT05770102
NCT03572192
NCT05514132
NCT06589414
Lead Sponsor
Debiopharm International SA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions